Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07712718 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 2 of 10 entries Show 5 more changesShow less
    • Trial completed
    • Final enrollment: 7 participants (planned 8)
    • Primary and study completion dates changed from estimate of Jul 2026 to Jul 8, 2026
    • Eligibility criteria expanded, about 12 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1, open label study in healthy male participants to study the Absorption, Distribution, Metabolism, and Excretion of \[14C\]-MRM-3379 drug following a single oral dose.
Trial Details
NCT Number NCT07712718
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Healthy Volunteers
Enrollment 7 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov